Showing 15 posts of 853 posts found.

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

NICE issues draft guidance recommending sapropterin for PKU in children

February 25, 2021
BioMarin, NICE, PKU

NICE has issued draft guidance which recommends BioMarin’s Kuvan (sapropterin) at a dose of up to 10 mg/kg for treating phenylketonuria …


NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021
Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …

NICE recommends treatments for pregnancy sickness in new draft guidance

February 11, 2021
NICE, Pregnant

NICE has recommended treatment options for severe pregnancy sickness for the first time, issuing recommendations in draft guidance published today.

NICE rejects multiple sclerosis drug Zeposia

January 22, 2021
Medical Communications NICE

NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In …


NICE recommends rheumatoid arthritis drug Jyseleca for NHS use

January 21, 2021
Gilead, NICE

NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …

NICE approves lipid disorder drug Myalepta for NHS use

January 20, 2021
Research and Development Amryt Pharma, NICE

NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …

NICE recommends cutting-edge lymphoma treatment for NHS use

January 19, 2021
Manufacturing and Production Cancer, NICE

NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …

NICE recommends GSK’s ZEJULA for advanced ovarian cancer

January 15, 2021
Medical Communications Cancer, GlaxoSmithKline, NICE

NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …

NICE recommends AstraZeneca’s FORXIGA for heart failure

January 7, 2021
AstraZeneca, NICE

NICE has issued a positive Final Appraisal Document (FAD) recommending AstraZeneca’s FORXIGA (dapagliflozin) as an option for treatment of symptomatic …

Shionogi’s novel antibiotic selected for UK pilot subscription reimbursement model

December 21, 2020
Sales and Marketing NICE, Shionogi, antibiotic

Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja …

NICE recommends GSK’s Nucala for more asthma patients

December 18, 2020
Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab

NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …


NICE recommends Novartis’ Beovu for wet age-related macular degeneration

December 16, 2020
Research and Development NICE, Novartis, wet AMD Beovu

NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …

NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

December 10, 2020
Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda

NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …

Latest content